Navigation Links
Pharmaceutical Product Commercialization: Enabling Teams to Excel
Date:11/9/2007

CHAPEL HILL, N.C., Nov. 9 /PRNewswire/ -- Pharmaceutical product teams have the power to make or break the launch of a new product. The problem is launch teams often lack the right structure, tools and processes to run effectively and therefore only produce a sub-optimal launch.

In fact, pharmaceutical marketing and HR executives agree that collaborative behavior and cross-functional team work are key ingredients during product commercialization. According to a study by pharmaceutical benchmarking firm Best Practices, LLC, many organizations still use fully operational cross-functional teams too infrequently.

Cross-function collaboration is greatly improved through many methods -- structuring jobs with overlapping responsibilities, basing rewards on group performance, designing procedures so that employees with different jobs are better able to collaborate, and laying out work areas so that people can see one another's work and share lessons learned.

"Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence," available with a complimentary study summary online at http://www3.best-in-class.com/rr878.htm, provides extensive insight into how pharmaceutical, biotech and medical device companies are building team communication and leadership structures that prepare employees to excel in a competitive marketplace.

Valuable best practices and operating tactics were gathered from leading pharmaceutical companies, including Amgen, Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis and Wyeth. They will help executives build and manage strong teams that can excel across functions, units and regions.

-- One benchmark partner aligned clinical and commercial's compensation,

bonuses and evaluation and saw a more unified approach to development

from the clinical and commercial sides. The alignment emphasizes the

goal of market success over any one functional activity.

-- The change came after the company found that its incentive programs

were major obstacles to the commercialization of the development

process. Scientists were rewarded for the number of INDs and NDAs they

submitted and cycle time for submission and approval. Marketing team

members were measured by market share and total sales.

-- While these two outlooks quite often conflict, eliminating sources of

friction in the incentives program has helped both groups work more

effectively to produce one of the company's recent successes.

For additional sample practices and metrics, download the free study summary at http://www3.best-in-class.com/rr878.htm.

This benchmarking report highlights the following areas of cross-functional team management:

-- Cross-Functional Team Structures

-- Collaboration and Productivity Processes

-- People Management

-- Decision-Making Processes

-- Communication and Collaboration

-- Resource Allocation

Download the complimentary excerpt at http://www3.best-in-class.com/rr878.htm or contact our Solution Specialists at (919) 403-0251 or bestpractices@best-in-class.com for more information.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when ... president of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and ... goals are cast aside. , That’s why one of her first decisions when her ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... businesses recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii ... , “Investing in like-minded companies who excel at service and response ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), ... the ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient ... , “Since our Pay It Forward program began, we are proud to ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... BioSciences, Inc. (NASDAQ: SGMO ), the leader ... quarter and full year 2015 financial results and ... editing," said Edward Lanphier, Sangamo,s president and chief ... leads the therapeutic genome editing field and we ... our ground-breaking genome editing programs through IND enabling ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
(Date:2/9/2016)... --  AllCare Plus Pharmacy announced today that it ... ® for Home Care Accreditation by ... Seal of Approval ® is a symbol of ... and effective care.  --> ... on-site survey in January 2016. The survey reflected compliance ...
Breaking Medicine Technology: